Seroatlas · Human Serome Atlas

PSMD2

26S proteasome non-ATPase regulatory subunit 2

Also known as: MGC14274, P97, PSMD2_HUMAN, Rpn1, S2, TRAP2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q13200
Gene: PSMD2
Ensembl: ENSG00000175166
Chromosome: 3
Canonical length: 908 aa
Protein class: Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Nucleoplasm,Cytokinetic bridge,Centriolar satellite,Cytosol,Flagellar centriole

OverviewNCBI Gene

The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes one of the non-ATPase subunits of the 19S regulator lid. In addition to participation in proteasome function, this subunit may also participate in the TNF signalling pathway since it interacts with the tumor necrosis factor type 1 receptor. A pseudogene has been identified on chromosome 1. Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

908 residues, UniProt reviewed canonical sequence.

>Q13200|PSMD2
     1  MEEGGRDKAP VQPQQSPAAA PGGTDEKPSG KERRDAGDKD KEQELSEEDK QLQDELEMLV
    61  ERLGEKDTSL YRPALEELRR QIRSSTTSMT SVPKPLKFLR PHYGKLKEIY ENMAPGENKR
   121  FAADIISVLA MTMSGERECL KYRLVGSQEE LASWGHEYVR HLAGEVAKEW QELDDAEKVQ
   181  REPLLTLVKE IVPYNMAHNA EHEACDLLME IEQVDMLEKD IDENAYAKVC LYLTSCVNYV
   241  PEPENSALLR CALGVFRKFS RFPEALRLAL MLNDMELVED IFTSCKDVVV QKQMAFMLGR
   301  HGVFLELSED VEEYEDLTEI MSNVQLNSNF LALARELDIM EPKVPDDIYK THLENNRFGG
   361  SGSQVDSARM NLASSFVNGF VNAAFGQDKL LTDDGNKWLY KNKDHGMLSA AASLGMILLW
   421  DVDGGLTQID KYLYSSEDYI KSGALLACGI VNSGVRNECD PALALLSDYV LHNSNTMRLG
   481  SIFGLGLAYA GSNREDVLTL LLPVMGDSKS SMEVAGVTAL ACGMIAVGSC NGDVTSTILQ
   541  TIMEKSETEL KDTYARWLPL GLGLNHLGKG EAIEAILAAL EVVSEPFRSF ANTLVDVCAY
   601  AGSGNVLKVQ QLLHICSEHF DSKEKEEDKD KKEKKDKDKK EAPADMGAHQ GVAVLGIALI
   661  AMGEEIGAEM ALRTFGHLLR YGEPTLRRAV PLALALISVS NPRLNILDTL SKFSHDADPE
   721  VSYNSIFAMG MVGSGTNNAR LAAMLRQLAQ YHAKDPNNLF MVRLAQGLTH LGKGTLTLCP
   781  YHSDRQLMSQ VAVAGLLTVL VSFLDVRNII LGKSHYVLYG LVAAMQPRML VTFDEELRPL
   841  PVSVRVGQAV DVVGQAGKPK TITGFQTHTT PVLLAHGERA ELATEEFLPV TPILEGFVIL
   901  RKNPNYDL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PSMD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.27
Highest tissue expression: 300 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 300 nTPM
tongue: 171 nTPM
heart muscle: 107 nTPM
adrenal gland: 93 nTPM
testis: 92 nTPM
esophagus: 79 nTPM

Single-cell type

syncytiotrophoblasts: 289 nCPM
late primary spermatocytes: 272 nCPM
cytotrophoblasts: 192 nCPM
esophageal apical cells: 189 nCPM
megakaryocytes: 173 nCPM
esophageal suprabasal cells: 156 nCPM

Immune cell

myeloid DC: 103 nTPM
total PBMC: 96 nTPM
classical monocyte: 86 nTPM
eosinophil: 82 nTPM
non-classical monocyte: 80 nTPM
NK-cell: 77 nTPM

Brain region

pons: 118 nTPM
midbrain: 111 nTPM
medulla oblongata: 96 nTPM
thalamus: 94 nTPM
hypothalamus: 93 nTPM
spinal cord: 84 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.1
gnomAD pLI: 1
gnomAD missense Z: 3.09
DepMap mean gene effect: -1.36
DepMap dependency class: pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 17% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

enzyme regulator activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

Proteasome/cyclosome repeat
Armadillo-like helical
Armadillo-type fold
Proteasome/cyclosome repeat
26S proteasome regulatory complex, non-ATPase subcomplex, Rpn1 subunit
RPN1, N-terminal
26S proteasome non-ATPase regulatory subunit RPN1, C-terminal
RPN1 N-terminal domain
26S proteasome non-ATPase regulatory subunit RPN1 C-terminal

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PSMD2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PSMD2 as an antibody target. Whether an autoantibody or antibody against PSMD2 could matter depends on whether native PSMD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PSMD2 is annotated as secreted, so native PSMD2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label PSMD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...